94 related articles for article (PubMed ID: 3625231)
1. Monoclonal antibody therapy in malignant melanoma: factors effecting in vivo localization.
Schroff RW; Morgan AC; Woodhouse CS; Abrams PG; Farrell MM; Carpenter BE; Oldham RK; Foon KA
J Biol Response Mod; 1987 Aug; 6(4):457-72. PubMed ID: 3625231
[TBL] [Abstract][Full Text] [Related]
2. Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen.
Schroff RW; Woodhouse CS; Foon KA; Oldham RK; Farrell MM; Klein RA; Morgan AC
J Natl Cancer Inst; 1985 Feb; 74(2):299-306. PubMed ID: 3883034
[TBL] [Abstract][Full Text] [Related]
3. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
4. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.
Schroff RW; Foon KA; Beatty SM; Oldham RK; Morgan AC
Cancer Res; 1985 Feb; 45(2):879-85. PubMed ID: 3871353
[TBL] [Abstract][Full Text] [Related]
5. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
[TBL] [Abstract][Full Text] [Related]
7. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.
Spitler LE; del Rio M; Khentigan A; Wedel NI; Brophy NA; Miller LL; Harkonen WS; Rosendorf LL; Lee HM; Mischak RP
Cancer Res; 1987 Mar; 47(6):1717-23. PubMed ID: 3493066
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
9. Toxicities associated with monoclonal antibody infusions in cancer patients.
Dillman RO; Beauregard JC; Jamieson M; Amox D; Halpern SE
Mol Biother; 1988; 1(2):81-5. PubMed ID: 3269251
[TBL] [Abstract][Full Text] [Related]
10. Evaluation and clinical relevance of patient immune responses to intravenous therapy with murine monoclonal antibodies conjugated to adriamycin.
Avner B; Swindell L; Sharp E; Liao SK; Ogden JR; Avner BP; Oldham RK
Mol Biother; 1991 Mar; 3(1):14-21. PubMed ID: 2069755
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.
Saleh MN; Khazaeli MB; Wheeler RH; Dropcho E; Liu T; Urist M; Miller DM; Lawson S; Dixon P; Russell CH
Cancer Res; 1992 Aug; 52(16):4342-7. PubMed ID: 1643631
[TBL] [Abstract][Full Text] [Related]
12. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.
Saleh MN; Khazaeli MB; Wheeler RH; Allen L; Tilden AB; Grizzle W; Reisfeld RA; Yu AL; Gillies SD; LoBuglio AF
Hum Antibodies Hybridomas; 1992 Jan; 3(1):19-24. PubMed ID: 1576319
[TBL] [Abstract][Full Text] [Related]
14. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
15. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
Kirkwood JM; Mascari RA; Edington HD; Rabkin MS; Day RS; Whiteside TL; Vlock DR; Shipe-Spotloe JM
Cancer; 2000 Jun; 88(12):2693-702. PubMed ID: 10870051
[TBL] [Abstract][Full Text] [Related]
16. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
17. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
18. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial.
Oratz R; Speyer JL; Wernz JC; Hochster H; Meyers M; Mischak R; Spitler LE
J Biol Response Mod; 1990 Aug; 9(4):345-54. PubMed ID: 2395000
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma.
Rosenblum MG; Murray JL; Haynie TP; Glenn HJ; Jahns MF; Benjamin RS; Frincke JM; Carlo DJ; Hersh EM
Cancer Res; 1985 May; 45(5):2382-6. PubMed ID: 3986780
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
